2-(R,S)-2-[(tert-butoxycarbonyl)amino]-4-(methylsulfanyl)-N-methylbutyramide | 1163250-07-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(R,S)-2-[(tert-butoxycarbonyl)amino]-4-(methylsulfanyl)-N-methylbutyramide
• 英文别名: (R)-2-(Boc-amino)-N-methyl-4-(methylthio)butanamide；tert-butyl N-[1-(methylamino)-4-methylsulfanyl-1-oxobutan-2-yl]carbamate
• CAS: 1163250-07-4
• 化学式: C₁₁H₂₂N₂O₃S
• 分子量: 262.373
• InChiKey: FYOUTJSPFQTMTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  453.4±40.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(R,S)-2-[(tert-butoxycarbonyl)amino]-4-(methylsulfanyl)-N-methylbutyramide 在 盐酸 、 氨 、 sodium 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 5-[3-(R,S)-3-amino-4-(N-methylcarboxamide)butylsulfanyl]pentanoic acid
  参考文献：
  名称：

  The development of a new class of inhibitors for betaine-homocysteine S-methyltransferase

  摘要：

  Betaine-homocysteine S-methyltransferase (BHMT) is an important zinc-dependent methyltransferase that uses betaine as the methyl donor for the remethylation of homocysteine to form methionine. In the liver, BHMT performs to half of the homocysteine remethylation. In this study, we systematically investigated the tolerance of the enzyme for modifications at the "homocysteine" part of the previously reported potent inhibitor (R,S)-5-(3-amino-3-carboxy-propylsulfanyl)-pentanoic acid (1). In the new compounds, which are S-alkylated homocysteine derivatives, we replaced the carboxylic group in the "homocysteine" part of inhibitor 1 with different isosteric moieties (tetrazole and oxadiazolone); we suppressed the carboxylic negative charge by amidations; we enhanced acidity by replacing the carboxylate with phosphonic or phosphinic acids; and we introduced pyrrolidine steric constraints. Some of these compounds display high affinity toward human BHMT and may be useful for further pharmacological studies of this enzyme. Although none of the new compounds were more potent inhibitors than the reference inhibitor 1, this study helped to completely define the structural requirements of the active site of BHMT and revealed the remarkable selectivity of the enzyme for homocysteine. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.039
• 作为产物：
  描述：

  DL-蛋氨酸 在 氯甲酸乙酯 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 1.0h， 生成 2-(R,S)-2-[(tert-butoxycarbonyl)amino]-4-(methylsulfanyl)-N-methylbutyramide
  参考文献：
  名称：

  The development of a new class of inhibitors for betaine-homocysteine S-methyltransferase

  摘要：

  Betaine-homocysteine S-methyltransferase (BHMT) is an important zinc-dependent methyltransferase that uses betaine as the methyl donor for the remethylation of homocysteine to form methionine. In the liver, BHMT performs to half of the homocysteine remethylation. In this study, we systematically investigated the tolerance of the enzyme for modifications at the "homocysteine" part of the previously reported potent inhibitor (R,S)-5-(3-amino-3-carboxy-propylsulfanyl)-pentanoic acid (1). In the new compounds, which are S-alkylated homocysteine derivatives, we replaced the carboxylic group in the "homocysteine" part of inhibitor 1 with different isosteric moieties (tetrazole and oxadiazolone); we suppressed the carboxylic negative charge by amidations; we enhanced acidity by replacing the carboxylate with phosphonic or phosphinic acids; and we introduced pyrrolidine steric constraints. Some of these compounds display high affinity toward human BHMT and may be useful for further pharmacological studies of this enzyme. Although none of the new compounds were more potent inhibitors than the reference inhibitor 1, this study helped to completely define the structural requirements of the active site of BHMT and revealed the remarkable selectivity of the enzyme for homocysteine. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.039

文献信息

• [EN] 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE 7-(MÉTHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE
  申请人：LILLY CO ELI

  公开号：WO2020123225A1

  公开（公告）日：2020-06-18

  The present invention provides a compound of Formula (I) wherein R is (II) or (III); or a pharmaceutically acceptable salt thereof, useful for treating psoriasis or systemic lupus erythematosus.

  本发明提供了一种化合物，其化学式为（I），其中R为（II）或（III）；或其药用可接受的盐，用于治疗牛皮癣或系统性红斑狼疮。
• [EN] 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE 7-(MÉTHYLAMINO) PYRAZOLO [1,5-A] PYRIMIDINE-3-CARBOXAMIDE
  申请人：LILLY CO ELI

  公开号：WO2021162942A1

  公开（公告）日：2021-08-19

  The present invention provides a compound of Formula (I) wherein R is (II), (III), (IV) or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.

  本发明提供了一种化合物，其化学式为（I），其中R为（II）、（III）、（IV）或其药用盐，用于治疗牛皮癣、系统性红斑狼疮或1型糖尿病。
• [EN] SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE 7-(MÉTHYLAMINO)PYRAZOLO [1,5-A]PYRIMIDINE-3-CARBOXAMIDE SUBSTITUÉS
  申请人：LILLY CO ELI

  公开号：WO2021162944A1

  公开（公告）日：2021-08-19

  The present invention provides a compound of Formula (I) wherein R is (II) or (III), or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.

  本发明提供了一种具有以下结构的化合物（I），其中R是（II）或（III），或其药用盐，用于治疗牛皮癣、系统性红斑狼疮或1型糖尿病。
• [EN] PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE UTILES DANS LE TRAITEMENT DU PSORIASIS ET DU LUPUS ÉRYTHÉMATEUX DISSÉMINÉ
  申请人：LILLY CO ELI

  公开号：WO2020055636A1

  公开（公告）日：2020-03-19

  The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.

  本发明提供了一种化合物，其化学式为I：其中R为甲基或乙基；或其药用可接受的盐，用于治疗牛皮癣或系统性红斑狼疮。
• PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3
  申请人：Desai C. Manoj

  公开号：US20070244109A1

  公开（公告）日：2007-10-18

  New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

  提供了基于新的吡咯基化合物、组合物和方法，用于体外抑制糖原合成酶激酶(GSK3)的活性和治疗GSK3介导的疾病。该发明的方法、化合物和组合物可单独应用，或与其他药理活性剂联合治疗GSK3活性介导的疾病，如糖尿病、阿尔茨海默病和其他神经退行性疾病、肥胖症、动脉粥样硬化性心血管疾病、原发性高血压、多囊卵巢综合征、X综合征、缺血、创伤性脑损伤、双相情感障碍、免疫缺陷或癌症。